Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus

Trial Profile

A Phase 1 Study of NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Carboplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Hafnium oxide (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors Nanobiotix
  • Most Recent Events

    • 21 May 2024 According to a Nanobiotix media release,Dose escalation part ongoing,the company expected to complete dose escalation part and initiation of dose expansion part in this year. first data will be presented in 2025.
    • 13 Nov 2023 According to a Nanobiotix media release, determination of RP2D in NSCLC trial, Completion of enrollment in Phase 1b dose expansion trial in pancreatic cancer, Initial Phase 1b/2 data in esophageal cancer data expected in 2024.
    • 08 Nov 2023 Planned End Date changed from 31 Oct 2022 to 31 Oct 2025.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top